{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:56:10Z","timestamp":1777895770126,"version":"3.51.4"},"reference-count":71,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Currently, few disease\u2010modifying therapies exist for degenerative movement disorders. Antisense oligonucleotides are small DNA oligonucleotides, usually encompassing \u223c20 base pairs, that can potentially target any messenger RNA of interest. Antisense oligonucleotides often contain modifications to the phosphate backbone, the sugar moiety, and the nucleotide base. The development of antisense oligonucleotide therapies spinal muscular atrophy and Duchenne muscular dystrophy suggest potentially wide\u2010ranging therapeutic applications for antisense oligonucleotides in neurology. Successes with these two diseases have heightened interest in academia and the pharmaceutical industry to develop antisense oligonucleotides for several movement disorders, including, spinocerebellar ataxias, Huntington's disease, and Parkinson's disease. Compared to small molecules, antisense oligonucleotide\u2013based therapies have an advantage because the target disease gene sequence is the immediate path to identifying the therapeutically effective complementary antisense oligonucleotide. In this review we describe the different types of antisense oligonucleotide chemistries and their potential use for the treatment of human movement disorders. \u00a9 2019 International Parkinson and Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.27782","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T15:34:11Z","timestamp":1562600051000},"page":"1112-1119","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Antisense therapies for movement disorders"],"prefix":"10.1002","volume":"34","author":[{"given":"Daniel R.","family":"Scoles","sequence":"first","affiliation":[{"name":"Department of Neurology University of Utah  175 North Medical Drive East, 5th Floor, Salt Lake City, Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan M.","family":"Pulst","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Utah  175 North Medical Drive East, 5th Floor, Salt Lake City, Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.1.280"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.21.7706"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.3.648"},{"key":"e_1_2_7_9_1","first-page":"2659","article-title":"Oligodeoxynucleotides as inhibitors of gene expression: a review","volume":"48","author":"Stein CA","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-58785-6"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/ard.1993.3.383"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.10.871-JMN0909-6-1"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000323"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010716-104846"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.010909.105654"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-3565(24)38831-7","article-title":"Pharmacokinetic properties of 2\u2032\u2010O\u2010(2\u2010methoxyethyl)\u2010modified oligonucleotide analogs in rats","volume":"296","author":"Geary RS","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(99)00150-5"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.01.008"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3779"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2003.09.014"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1039\/c1cs15048k"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gki193"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.10.5633"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl1071"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3948"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99081"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh997"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3120599"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw065"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1196-269"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0660-09.2009"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.26377"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005182"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06041-3"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22044"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2011.11.006"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1515\/bc.2011.045"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.06.019"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25264"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.04.005"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(01)00422-6"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aap8677"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.02.003"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.201"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2012.09.001"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7618107"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90542-1"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1095-155"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.05.009"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi101208k"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.09.011"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.09.010"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12312"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2909168"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13623"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.04.006"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00338"},{"issue":"1","key":"e_1_2_7_58_1","first-page":"S123","article-title":"Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration","volume":"33","author":"Wang JZ","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02513.x"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12208"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2107-13.2013"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0481"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.30"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00028"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20180464"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-016-0140-1"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3642-15.2016"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.07.025"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.08.002"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.11.015"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.08.2950"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/0958-1669(91)90022-W"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.27782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.27782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.27782","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.27782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:52:03Z","timestamp":1760950323000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.27782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1002\/mds.27782"],"URL":"https:\/\/doi.org\/10.1002\/mds.27782","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"2018-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}